Amgen (AMGN) has re-entered the Unfavored zone, falling 28 spots in a month to 53rd in the SIA S&P 100 Index Report, with a 12.2% decline in contrast to the market and sector gains 5.3% and 4.75%, respectively. Technical indicators point to a new downtrend, with critical support at $260.00 and resistance at $283.00.